SGYP Synergy Pharmaceuticals, Inc.

5.09
+0  (0%)
Previous Close 5.07
Open 5.03
Price To book 27.41
Market Cap 1.14B
Shares 223,115,000
Volume 4,790,735
Short Ratio 5.98
Av. Daily Volume 7,083,660

SEC filingsSee all SEC filings

  1. 8-K - Current report 17703902
  2. 8-K - Current report 17687083
  3. 8-K - Current report 17658655
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17655390
  5. 8-K - Current report 17613402

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from first and second trials met primary endpoints - December 9 and 22, 2016. NDA filing due 1Q 2017.
Plecanatide
Constipation-predominant irritable bowel syndrome (IBS-C)
Approved January 19, 2017.
Trulance (plecanatide)
Chronic idiopathic constipation (CIC)
Phase 1b data released January 2016. Phase 2 planned.
Dolcanatide
Mild-to-moderate ulcerative colitis

Latest News

  1. SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  2. SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  3. Synergy Pharmaceuticals to Present at Oppenheimer 27th Annual Healthcare Conference
  4. Synergy Pharmaceuticals: Approval, Now What?
  5. SYNERGY PHARMACEUTICALS, INC. Financials
  6. CORRECTING and REPLACING Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update
  7. SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
  8. SYNERGY PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
  9. Synergy Pharma reports 4Q loss
  10. Synergy Pharma reports 4Q loss
  11. Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update
  12. Did 50 Salespeople Leave Valeant? Wells Fargo Investigates
  13. SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  14. SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  15. Synergy Pharmaceuticals to Present at Leerink Partners 6th Annual Global Healthcare Conference
  16. SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  17. Pivotal Phase 3 Data Results for TRULANCE™ (plecanatide) in the Treatment of Chronic Idiopathic Constipation (CIC) Published in American Journal of Gastroenterology
  18. Price For Synergy Pharmaceuticals Inc (SGYP) Public Offering Announced
  19. SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial
  20. Why Synergy Pharmaceuticals Shares Fell 14.6% Today